SEARCH:      Monitor Keywords |  Custom RSS

Organic compounds -- part of the class 532-570 series April category listing, related patent applications 04/10

20100105897 - Novel quinuclidine derivative useful in the preparation of mequitazine: The invention relates to a 1-aza-bicyclo[2.2.2]oct-2-en-3-ylmethyl acetate of the formula (I), wherein said compound is useful as a synthesis intermediate for the production of mequitazine.... Agent: Birch Stewart Kolasch & Birch

20100105898 - Method for producing scopinium salts: e

20100105899 - Integrated photoactive small molecules and uses thereof: This invention is directed to the general method of transforming non-photoactive bioactive small molecule compounds of known structure and function into photoactive analogs of the small molecules which exhibit both photoactivity and the original biological targeting activity. The general method for the design of the photoactive analogs of the small... Agent: Mallinckrodt Inc.

20100105900 - Inhibitors of carnitine palmitoyltransferase and treating cancer: A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to... Agent: Foley & Lardner LLP

20100105901 - Synthesis method of polymer complex crystal: Specifically disclosed is a synthesis method of a polymer complex crystal wherein (1) a metallic solution, which is a mixture of zinc halide(II) and a solvent A that can dissolve the zinc halide, is mixed with (2) a ligand solution, which is a mixture of a tridentate ligand that has... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20100105902 - Organometallic complex, and light-emitting element, light-emitting device, and electronic device including the organometallic complex: An organometallic complex is provided by which favorable red-color light emission can be obtained. Further, an organometallic complex having a peak of light emission at about 620 nm is provided because the wavelength of light which is perceived as excellent red-color light is about 620 nm. Furthermore, an organometallic complex... Agent: Cook Alex Ltd

20100105903 - Method for the production of beta-ketonitriles:

20100105904 - Urea type cinnamide derivative: (In the formula, Ar1 represents an imidazolyl group which may be substituted with a C1-6 alkyl group; Ar2 represents a phenyl group which may be substituted with a C1-6 alkoxy group; X1 represents a single bond; R1 and R2 respectively represent a C1-6 alkyl group or the like which may... Agent: Birch Stewart Kolasch & Birch

20100105905 - Ep2 agonists: The invention provides EP2 agonists, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for lowering intraocular pressure and thereby treating glaucoma.... Agent: Pfizer Inc

20100105906 - Novel phenyl amide or pyridyl amide derivatives: e

20100105907 - Continuous antisolvent crystallization process and system using plug flow reactors: A process and system for continuous crystallization of a compound using antisolvent addition in which a solution is prepared with an organic compound and a solvent. An antisolvent is added to the solution in a continuous plug flow system comprising at least one process module. The antisolvent can be added... Agent: Smith, Gambrell & Russell

20100105908 - Process for the preparation of levocetirizine and intermediates thereof: The present invention describes a novel process for the preparation of levocetirizine and pharmaceutically acceptable acid addition salts thereof using diglycolic acid or derivatives thereof and new intermediates used in that process.... Agent: Swanson & Bratschun, L.L.C.

20100099866 - Organosilicon compound having amino group and its production method: wherein R1 and R2 respectively represent an unsubstituted or substituted aliphatic monovalent hydrocarbon group containing 1 to 10 carbon atoms with the proviso that the R1 and R2 may together form a ring with the nitrogen atom to which they are bonded, and that R1 and R2 may contain a... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100099867 - Process for the preparation of tiotropium bromide: The invention is directed to improved processes for preparing Tiotropium bromide.... Agent: Merchant & Gould PC

20100099868 - Biological buffers with wide buffering ranges: Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be buffered. The reaction of amines or polyamines with various molecules to form polyamines with differing pKa's will extend the buffering range, derivatives that result in... Agent: Clifford H. Kraft

20100099869 - Novel nucleotide analogues as precusor molecules for antivirals: This invention relates to a purine or pyrimidine phosphonate compound of formula (I) or pharmaceutically acceptable salt thereof; wherein B, X, and R1-R3 are as defined in classes and subclasses herein. These compounds may be used as antiviral precursors. The invention also relates to therapeutic compositions of these compounds and... Agent: Arent Fox LLP

20100099870 - Novel adenine compound: [wherein R1 is substituted or unsubstituted alkyl, etc., X is oxygen, etc., A1 is 4- to 8-membered substituted or unsubstituted saturated nitrogen-containing heterocycle containing 1 to 2 hetero atom(s) selected from 1 to 2 nitrogen(s), 0 to 1 oxygen and 0 to 1 sulfur, etc., A2 is substituted or unsubstituted... Agent: Birch Stewart Kolasch & Birch

20100099871 - Novel adenine compound: Compounds having anti-psychotic activity are disclosed herein. In some embodiments, the compounds are atypical anti-psychotics. In some embodiments, the compounds are selective for the 5-HT2A receptor over the D2 receptor. Pharmaceutical derivatives and pharmaceutical compositions including the compounds are disclosed herein. Methods for treating a psychotic condition that include administering... Agent: Winstead PC

20100099872 - Production method for ethyleneamine mixtures: The invention relates to a process for preparing an ethylene amine mixture, which comprises hydrogenating an amino nitrile mixture comprising at least two α-amino nitriles in an amount of at least 5% by weight in each case in the presence of a catalyst and, if appropriate, a solvent.... Agent: Connolly Bove Lodge & Hutz, LLP

20100087638 - Process for the preparation of lamotrigine: A novel process for the preparation of lamotrigine and its intermediates is devised.... Agent: Hoffmann & Baron, LLP

20100087639 - Process for the preparation of tertiary n-allyl sterically hindered amines: The instant invention discloses a process for the preparation of compounds of the formula (I), wherein the general symbols are as defined in claim 1, which process comprises reacting a sterically hindered amine of the formula (II), wherein the general symbols are as defined in claim 1, with a compound... Agent: Ciba Corporation Patent Department

20100087640 - Method for production of aryl-substituted annelated pyrimidines: e

20100087641 - Method and materials for quaternary amine catalyzed bisulfite conversion of cytosine to uracil: The invention provides methods and materials for the conversion of cytosine to uracil. A nucleic acid, such a gDNA, is reacted with bisulfate, such as magnesium bisulfite, in the presence of a quaternary amine catalyst. Examples of suitable quaternary amine catalysts include but are not limited to quaternary ammonium compounds,... Agent: Life Technologies Corporation C/o Intellevate

20100087642 - Catalysis of diketopiperazine synthesis: Provided is a method for the synthesis of N-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ε-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.... Agent: K&l Gates LLP

20100087643 - Method for producing optically active 2-arylpiperazine derivative: The objective of the present invention is to produce an optically active 2-arylpiperazine derivative useful as a synthetic intermediate for pharmaceutical products and agricultural chemicals from inexpensive and readily available starting material by an industrially practicable method. The objective can be accomplished by treating an optically active substituted aminodiol derivative... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100081804 - Process for continuous hydrogenation or hydrogenating amination: A process is described for continuously hydrogenating unsaturated compounds, in which particles of a first hydrogenation catalyst are suspended in a liquid phase in which an unsaturated compound is dissolved, the liquid phase, in the presence of a hydrogenous gas at a first partial hydrogen pressure and at a first... Agent: Connolly Bove Lodge & Hutz LLP

20100081806 - Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support: The invention is directed to compounds and methods of synthesizing hydroxyethlamino amides and their use in treatment of aspartyl protease mediated diseases and conditions.... Agent: Philip S. Johnson Johnson & Johnson

20100081805 - Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide: e

20100081807 - Method for producing 5-cloro-n-(methyl)-2-thiophenecarboxamide: The invention relates to a method for producing 5-chloro-N-({5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide starting from 5-chlorothiophene-2-carbonyl chloride, (2S)-3-amino-propane-1,2-diol and 4-(4-aminophenyl)-3-morpholinone.... Agent: Connolly Bove Lodge & Hutz, LLP

20100081808 - Process for production of optically active epoxy compound: [Means For Solving Problems] The process for producing an optically active epoxy compound comprises asymmetrically epoxidizing an unsaturated compound with an oxidizing agent in the presence of an optically active titanium-salen complex, an optically active titanium-salalen complex or an optically active titanium-salan complex, with addition of a buffering agent or... Agent: Oliff & Berridge, PLC

20100081809 - Amorphous valganciclovir hydrochloride: The present application relates to amorphous forms of valganciclovir salts such as the hydrochloride and processes for their preparation.... Agent: Dr. Reddy''s Laboratories, Inc.

20100081810 - C-pyrazole a2a receptor agonists: 2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.... Agent: Swiss Tanner, P.C. P.o. Box 1749

20100081811 - Method for the nitration of 4,6-dihydroxy-2-methylpyrimidine: Disclosed is a method for the nitration of 4,6-dihydroxy-2-methylpyrimidine for the synthesis of 4,6-dihydroxy-5,5-dinitro-2-(dinitromethylene)-2,5-dihydropyrimidine which is used as a precursor of 1,1-diamino-2,2-dinitroethylene, one type of explosives. The present invention provides an improved method for the nitration of 4,6-dihydroxy-2-methylpyrimidine, wherein organic solvent is applied in the nitration process of 4,6-dihydroxy-2-methylpyrimidine thereby... Agent: Young & Thompson

20100081812 - Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders: Substituted pyrimidine derivatives of formula (I), salts, metabolites, prodrugs and diastereoisomeric forms (both isolated stereoisomers and mixtures of stereoisomers) thereof (wherein A=pyrimidine) pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with other... Agent: Millen, White, Zelano & Branigan, P.C.